Trending...
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- Koplon Dentistry Elevates Implant Expertise with Advanced CE Course
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- The Citizens Commission on Human Rights of Florida Celebrates Volunteers and Community Partners at the 9th Annual Humanitarian Awards Banquet
- J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
- Words of Veterans & Veterans Growing America Collaboration
- Mature Athlete - Want Elite, Web-Based Nutrition and Training Coaching?
- Engaged at Any Age: 73-Year-Old Client Finds True Love Through Elite Asian Matchmaker
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- $73.6 Million in Order Backlog Poised for Explosive Growth in 2026; Streamlined Share Structure: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Osric Langevin Unveils "Quantitative Trend" Framework for Multi-Asset Analysis in Q4 2025
- Experience Days Named Among the UK's Top Christmas Gifts
- New Free Educational Bingo Cards Make Learning English Fun for First Graders
- Wzzph Provides Stablecoin Trading Solutions for Latin American Traders Amid Digital Currency Policy Adjustments
- Kilmer Construction Announces Seasonal Savings on Home Improvements in Northeastern PA
- NaturismRE Calls for Recognition of AI as Sentient Kin in Global Bill of Rights
- PDS Plumbing & Air Honors Veterans with "Free Tune-Up & A Turkey" Giveaway
- AgeImmune Announces the Launch of ImmuneG.I. — A Doctor-Formulated Herbal Supplement Supporting Gut and Digestive Wellness
- Precision Adult Care Unveils Essential Guidelines for Choosing a Senior Home Care Company
- Postmortem Pathology Delivers Expert Private Autopsy Services with Compassion and Precision
- Colorado Families Turn to Private Autopsies for Peace of Mind
- $5.4 Million Growth Acceleration, Fleet Expansion and $1.485 Million Strategic Financing: Multi Ways Holdings (N Y S E: MWG) $MWG
- Delta Capital Group Expands Business Funding Terms Up to 24 Months
- Hip-HopVibe.com Launches HHV Media Network in Partnership with The Publisher Desk
- Patient Weather introduces POI, the Peterlin OxyWeather Index
- CCHR: Misinformation Clouds Debate on Psychiatric Drug Toxicology Transparency
- Hilton Head Realtor becomes Certified Senior Professional
- Bitcoin at $115K: AZETHIO Launches Exchange Targeting Institutional Compliance Requirements
- Tech gains propel Dow Jones past 47,000 as markets reach record highs amid trade tensions